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Carbon Nanotube Membranes for use in the Transdermal
Treatment of Nicotine Addiction and Opioid Withdrawal
Symptoms
Caroline L. Strasinger 1, Nicole N. Scheff 1, Ji Wu 2, Bruce J. Hinds 2
and Audra L. Stinchcomb 1
1

Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, U.S.A. 2Department
of Chemical and Materials Engineering, University of Kentucky, Lexington, KY, U.S.A.
Abstract: Transdermal systems are attractive methods of drug administration specifically when treating patients for drug
addiction. Current systems however are deficient in therapies that allow variable flux values of drug, such as nicotine for
smoking cessation or complex dosing regimens using clonidine when treating opioid withdrawal symptoms. Through the
use of functionalized carbon nanotube (CNT) membranes, drug delivery to the skin can be controlled by applying a small
electrical bias to create a programmable drug delivery system. Clearly, a transdermal patch system that can be tailored to an
individual’s needs will increase patient compliance as well as provide much more efficient therapy. The purpose of this paper
is to discuss the applicability of using carbon nanotube membranes in transdermal systems for treatment of drug abuse.
Keywords: transdermal delivery, variable rate, CNT, nicotine, clonidine

Introduction

Drug abuse, whether alcohol, tobacco, prescription or illicit, continues to burden society, economics,
medical care systems, and the family dynamic. The World Health Organization (WHO) estimates that
globally 185 million people are illicit drug users and an astounding 1.3 billion individuals are smokers.1
Smoking related deaths, estimated at nearly 5 million worldwide, continue to be the leading preventable
cause of death. Additionally, in the United States alone, $167 billion in annual health-related economic
loss can be attributed to smoking.2 Although there are roughly only 200,000 deaths reported to be
directly associated with illicit drug use, the detriment to family and society, and the economic costs
associated with crime, law enforcement, medical care, and drug treatment and rehabilitation, are
immense.3,4 While current treatments for cigarette smoking and opioid addiction do aid in successful
abstinence from the individual’s vice, there is great need and room for improvement. The best of smoking cessation therapies reports a mere 19% success after one year, while only 50% of individuals who
enter clinics for opioid addiction remain for the duration of the treatment, of which 65% return to using
within 4 weeks.3,5 Clearly, a therapy that better controls cravings or abates withdrawal symptoms to
decrease the likelihood of relapse is needed. Carbon nanotube (CNT) membranes present the opportunity to create a transdermal patch that can vary its rate of delivery throughout its application to the skin
to attain therapeutic plasma levels and plasma profiles of a specific drug. The purpose of this report is
to discuss the use of carbon nanotube membranes in a transdermal system to aid in abstinence from
cigarettes and withdrawal from opioids.

Nicotine and Clonidine as Therapies

Conventional nicotine replacement therapy (NRT) has been on the market since the early 1990s.
Continuous research and development of the therapy has expanded the delivery from early reservoir
transdermal patches to matrix systems, gums, inhalers, lozenges, and nasal sprays.6 As the name implies,
NRT works to replace nicotine, the agent in cigarettes responsible for dependence, with a pure pharmaceutical source, thereby eliminating the toxic chemicals found in tobacco smoke from entering the
body. Furthermore, NRT prevents withdrawal symptoms which induce the desire to smoke, thereby
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by a return to baseline levels, and then later be
reactivated when a craving occurs, would be beneficial to someone attempting to abstain from
smoking. Furthermore, a system that can be
tailored to an individual’s smoking schedule would
provide a more efficacious treatment than a standard “one size fits all” therapy.
Similarly, a multiple rate delivery system would
be beneficial to patients and medical staff when
treating opiate withdrawal symptoms using clonidine. Currently, clonidine is used in rehabilitation
clinics to mitigate the symptoms of opiate withdrawal including rhinorrhea, lacrimation, perspiration, piloerection, gastrointestinal complaints,
nausea, yawning, sneezing, muscle pain, tachycardia
and hypertension.4 Clonidine is a partial pre- and
postsynaptic alpha-adrenoreceptor agonist that
produces a reduction in peripheral sympathetic
outflow. Patients experience acute withdrawal
symptoms between 6 to 12 hours after opioid
abstinence with peak effects being felt between
36 to 72 hours and gradual abatement over 5 to
10 days.3,9 For this reason patients are typically
given multiple oral clonidine doses, or in a few
cases a combination of transdermal and oral drug,
per day during treatment.4,5 A typical five day oral
treatment profile can be seen in Figure 1b. Clearly,
repetitive dosing with variable amounts each day
puts a strain on the patient and clinical staff.
Patients who are experiencing withdrawal are
likely irritable and unreceptive to medical staff

Nicotine plasma concentration

increasing a smoker’s ability to put up with the
environmental and social cues associated with
smoking. Though current NRTs do aid in smoking
cessation when compared to individuals who try
to quit using non-pharmacological treatment or are
given placebos, the success rate is still an unsatisfactory 17%.3 A representative daily nicotine
plasma profile of a heavy smoker can be seen in
Figure 1a. It consists of a series of peaks and
troughs spurred by the smoking of each cigarette
with rapid, less than five minutes, attainment of
the maximum nicotine level. Slight accumulation
can be seen over the course of the day, but the high
spike of nicotine is always obtained with the
smoking of a new cigarette.7 NRT’s low success
rate is primarily due to the fact that no current
system can actually mimic the rapid attainment of
high nicotine plasma levels associated with smoking a cigarette.3,8 Nasal spray offers the fastest time
of delivery to its maximum concentration, but does
not reach the level required to suppress a nicotine
craving of a smoker, and like the gum, lozenge or
inhaler it requires multiple doses throughout the
day which often leads to issues with patient
compliance. The current transdermal patch is a
once daily application, however it cannot safely
deliver the craving sustaining dose, nor can the
system deliver it in a rapid manner, mimicking
the smoking plasma profile.6 Clearly, a delivery
system that can rapidly and safely deliver nicotine
at a level equal to that of a cigarette, followed

Time (h)
Figure 1a. Representative nicotine plasma profile of a cigarette smoker. Asterisks indicate the smoking of a cigarette.
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Figure 1b. Representative 5 day opioid withdrawal symptom treatment with clonidine dosing scheme. On day one two 0.1 mg doses are
given for a total of 0.2 mg of clonidine, on day two three doses are given and so on.

who must administer the multiple doses of a drug
per day. Additionally, patients who suffer nausea
and gastrointestinal problems during withdrawal
experience difficulties in maintaining proper doses
due to vomiting. A transdermal system that can
manipulate its delivery rate to provide the required
dose on specific days during a typical clinic stay
would not only eliminate the physiological dosing
issues, but also ease the burden of administering,
monitoring, and tailoring a drug regimen to each
individual patient.
Transdermal patches tend to be one of the most
desired therapies by patients and health care providers, not only for easy and pain-free administration, but also for several pharmacokinetic and
pharmacodynamic benefits.10,11 Traditional transdermal delivery allows one time application to
constantly administer drug over a given time,
thereby eliminating the hassle and difficulties
associated with oral or intravenous maintenance
multiple dosing. This “worry free” administration
increases patient compliance, which is essential
when trying to combat drug addiction. Additionally, once a drug passes through the upper echelons
of the skin, it is directly taken into systemic circulation by the highly vascularized dermal layers.
This affords the opportunity to lower the amount
of drug required at the administration site, because
of the avoidance of first pass metabolism. Not only
is this more cost effective, but also safer for the
patient as high levels of compounds can increase
the chance for toxicity. Furthermore, as mentioned
previously, gastrointestinal complications can lead
to difficult and improper oral dosing when treating
Substance Abuse: Research and Treatment 2009:3

patients experiencing opioid withdrawal symptoms.
Such symptoms would not hamper therapeutic
regimen designs when delivering the desired pharmaceutical agent transdermally. Despite the attractiveness of the transdermal route, one major
shortcoming exists in efficaciously treating smoking and opioid addiction with currently available
patches; none of the current marketable transdermal patches can deliver the required variable
dosing rate of drug to effectively treat these addictions in a single, self-contained system. The use of
CNT membranes in a transdermal system offers a
feasible solution to this variable rate drug delivery
predicament.

Carbon Nanotube Membranes

The demand for development of highly functionalized chemical screening, separating, purifying and
delivery devices has risen in the past several
decades as vast advances in the areas of biology,
chemistry, electronics and medicine continue to be
made.12 Nanoporous membranes consisting of
aligned, multi-walled CNTs in a polymer substrate,
possessing distinctive properties have demonstrated their applicability in the areas of electronic
devices, chemical separation, biosensors, salt water
desalination and purification, and most recently, in
the area of drug delivery. More specifically, three
significant properties unique to CNT membranes
that can be utilized to conquer the difficulties of a
variable rate drug therapy are 1) extremely fast
fluid flow due to graphite planes and large van der
Waals distance,13 2) well defined geometry of
33
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ligands at pore entrance resulting from membrane
synthesis,14 and 3) the concentration of an electric
field at the tips of CNTs due to their electrically
conductive properties while surrounded by an
insulating polymer support.15 Synthesis of these
membranes has been described previously,16 but
briefly carbon nanotube arrays are grown by
chemical vapor deposition (CVD) on a quartz
substrate using specific metal catalysts to control
the diameter of nanotubes. The spaces between the
individual tubes are then embedded with a polymer
substrate and the quartz support etched off using
hydrofluoric acid. H2O plasma oxidation is utilized
to remove excess polymer on the surface of the
film as well as the initial growth catalyst particle.
This process results in a robust membrane with
open-ended CNTs possessing carboxylic functionality at the tips. These tips can be further functionalized with various molecules using carbodiimide
chemistry to create charged molecular chains that,
with proper electrical influence, will work as a gate
to chemical transport through the nanotubes.15
More specifically and as seen in Figure 2, by applying a small electrical bias (⬍50 mV) to the membrane, the end groups, which are negatively
charged, are either attracted to the nanotubes themselves causing blockage of the pore and thus no
transport, or repelled from one another and surrounding nanotubes causing the functional group
to stand on end allowing fluid passage and drug

delivery through the pore. By incorporating this
voltage gated membrane into a transdermal system
(Fig. 3a), programmable controlled dosing either
by physician or patient is attainable.
Recall that the major set back in current NRT
therapies is the inability to mimic the actual pulsatile nicotine delivery profile and resultant peak
plasma levels of a smoker. With the ability of a
patch to deliver a high dose of nicotine and then
safely shut off to return to baseline plasma levels
throughout the day, a smoker would be able to
satisfy their nicotine craving and thereby increase
their chances of becoming smoking independent.
Furthermore, these patches can be patient controlled through a push activated button pressed
at the initiation of a patient’s craving, which
would apply the electrical bias to the membrane
allowing drug flow to the skin, eliminating patient
to patient tailoring issues seen with conventional
therapies. As with all drug addiction and subsequent pharmacological replacement treatment,
the patient must be motivated to quit to truly gain
independence from whatever drug one is dependent upon.
Similarly, the multiple and variable dosages
that are utilized to properly treat opioid withdrawal
symptoms can be simplified to a one time application and computer chip controlled transdermal flux
change system. Using multiple membranes within
the patch will allow for a therapy that is patient

Figure 2a. No or limited drug diffusion (depending on the size of the attached dendrimer) occurs when a positive bias is applied to the
membrane. Each nanotube has multiple dendrimers attached to opening as shown in the inset, for simplification purposes only one is shown
in the larger figures.
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Figure 2b. Drug passes through the nanotubes when a negative bias is applied. The dendrimers remain upright opening the tube because
of the surrounding negative charges as shown by the arrows.

tailorable and highly desirable for both patient and
medical staff. Using the setup seen in 3b, the
typical clonidine dosing profile previously discussed can be achieved by activating one side of
the patch the first and fourth day, activating both
membranes the second and third day for the
highest transdermal flux, and by activating only
the second membrane the fifth day to taper down
the dose.
As alluded to earlier, abusers going through
withdrawal may experience increased sweating,
variable circulation and based on the degree of

withdrawal, craving, or intoxication may be quite
different from patient to patient.17 This variability
in skin conductance could introduce problems in
traditional transdermal delivery; however one of
the main advantages of the CNT membrane system
is its increased dosing flexibility. More specifically,
the system cannot only be tailored to an individual
patient’s needs, but also possesses the added benefit of flexibility in drug delivery as conditions
change over the course of treatment. Because of
the high doses of nicotine required to effectively
treat smoking addiction with this nanotube system

Patch Cover
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Figure 3a. Schematic of patch layering using one CNT membrane to produce two different transdermal fluxes.
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Figure 3b. Schematic of patch layering using two CNT membranes to produce three different transdermal fluxes.

and the fact that the system will be patient activated,
the potential for lethal overdose is a possibility
without a proper design. For this reason the patch
will require a multi-use lockout system; the first
facet to automatically shut off the patch when the
proper nicotine amount is delivered, the second to
prevent the addicted individual from activating the
patch too often and delivering too much nicotine in
a short time period. The proper amount of nicotine
refers to the required amount of drug to be delivered
transdermally that corresponds to the nicotine
plasma levels seen immediately following the smoking of a cigarette.Additionally, as discussed, this
patch setup will involve the use of a small electric
current to deliver the drug. Currently marketed
transdermal iontophoresis systems also use electric
current to deliver drug. However, unlike iontophoresis, the electrodes used to deliver the bias are never
in contact with the skin, nor is the voltage required
as high; 50 mV for the CNT system compared to
10 V for iontophoresis.15,18 For these reasons the
skin irritation and lesions that are often seen with
the iontophoretic set up are not expected when using
CNT membranes in a transdermal patch.19
The use of CNT membranes in transdermal
therapy is fairly cost effective as the membranes
themselves can be fashioned for as little as
$0.60/m2. The bulk of the cost of this transdermal
set up will come from cost of drug and the bias
control system. The cost of drug will obviously be
comparable to that of current nicotine and clonidine
transdermal therapies. The voltage required to
36

activate and deactivate the system is no more than
that which can be supplied by a watch battery, and
the mechanics of the system, electrodes to provide
the bias, is comparable to that of the new patient
activated iontophoteric fentanyl delivery system
marketed as IONSYSTM.20 Additionally, the voltage system would be able to be reused, making the
drug the only continuous expense throughout the
therapy.

Therapeutic Feasibility

Despite the simplicity of the system, it was still
essential to demonstrate that the skin alone could
permit the required maximum transdermal flux,
proper rate changes, and especially in the case of
nicotine delivery, do so with minimal lag time.
A series of proof-of-concept in vitro diffusion studies were conducted on excised human abdominal
skin in order to determine if the three parameters
discussed were feasible for each drug. The average
smoker has a steady-state nicotine plasma concentration of about 10–20 ng/ml with peak levels
reaching approximately 54 ng/ml throughout the
day with each cigarette.7 Using equation 1 in which
J is the steady-state transdermal flux, Css is the
steady-state plasma concentration, Cl is the total
body clearance of nicotine, and A is the diffusional
area (7 cm2), these plasma levels translate to a
required transdermal flux of 0.8 μmol/cm2/h and
4 μmol/cm2/h for steady-state and peak nicotine
concentrations, respectively. For a traditional
Substance Abuse: Research and Treatment 2009:3
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five-day opioid withdrawal symptom treatment
regimen using clonidine, the first and fourth days
require a total of 0.2 mg per day of oral clonidine,
days two and three a total of 0.3 mg per day, and
the fifth day 0.1 mg of oral clonidine as seen in
Figure 1b.5 Using a patch size of 10 cm2, 100%
bioavailability,21 and each day’s oral dose over a
24 hour period, effective transdermal fluxes of
3.5 nmol/cm2/h, 5.4 nmol/cm2/h, and 1.7 nmol/cm2/h
can be estimated.
J=

Css Cl
A

(1)

Human skin from abdominoplasty surgery was
obtained from the National Cancer Institute’s
Cooperative Human Tissue Network (CHTN). The
samples were dermatomed immediately upon
arrival to a thickness of approximately 200 μm and
frozen at −20 °C. On the day of the experiment,
the skin was thawed and immediately used for the
diffusion studies. The abdominal skin was loaded
into a cell of a PermeGear® In-Line Diffusion
apparatus (Bethlehem, PA, U.S.A) and charged
with 250 μl of desired drug solution, and temperature was maintained at 35 °C (skin surface temperature) by a circulating water bath.22 Solutions
of 0.9% saline for nicotine and 0.9% saline with
10% ethanol for clonidine were prepared for use
as the receiver solutions for diffusion. Multiple
donor concentrations were used in order to simulate a CNT change in drug supply to the skin surface to determine whether a flux change would be
observed through the skin, and to see its associated
transition (lag) time for rate change. For example,
after it was determined that a nicotine donor concentration of 500 mg/ml would produce the desired
4 μmol/cm2/h flux, this donor solution was applied

to the skin and the receiver solution was sampled
over 30 minutes. Next, the donor solution was
removed and the skin and diffusion cell donor
chamber quickly rinsed with water to remove any
residual nicotine on the surface, and a much lower
donor solution concentration of 50 mg/ml was used
in order to observe a flux change and lag time to
flux change. After another 30 minutes of receiver
solution sampling, the skin and cell chamber were
washed again and a donor solution of 500 mg/ml
was reapplied to the skin, and the receiver solution
sampled again. This process mimics the activation
of the carbon nanotube membrane to allow more
drug flow, followed by deactivation and then reactivation, much like a person smoking two cigarettes
over an hour and a half period. Transition times
were observed and results can be seen in Table 1.
The term transition time for this work refers to the
time it takes between a change in drug rate supply
to reach the new desired steady-state concentration
in the receiver solution.
It was also important to investigate the rate of
drug delivery out of the skin after a donor concentration was removed, in other words the depletion
of nicotine from the skin after the patch is turned
off. The residual drug amount that is in the skin
after the patch is shut off or removed will enter
systemic circulation and must be taken into consideration when determining the proper time to
allot between patient initiated activation. For this
study, varying donor solution concentrations (200,
300, 400, 500 mg/ml) were applied to the skin
long enough to reach steady state, and then
removed and the cell chamber and skin briefly
washed with water. Sampling of the receiver solution was continued for approximately two hours
with no donor solution on the skin in order to
observe nicotine depletion. These studies resulted

Table 1. Therapeutic transdermal fluxes and transition times for nicotine and clonidine (n = 4).

Nicotine

Clonidine

Concentration
(mg/ml)

Transdermal flux
(μmol/cm2/h)

Transition
time (min)

500

4.27 ± 0.22

4.7 ± 0.4

50

1.48 ± 0.22

0

500

4.23 ± 0.25

5.5 ± 0.5

0.225

0.0037 ± 0.00100

322 ± 59*

0.325

0.0053 ± 0.00068

N/A

0.160

0.0021 ± 0.00096

N/A

*Initial lag time for the first dose.
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in the model seen in Equation 2, where the
variables correspond to Figure 4 and k is the time
constant which was 0.088 ± 0.0092 min−1 (Graphpad Prism®, La Jolla, CA, U.S.A) and independent of donor concentration (p ⬎ 0.05) (one-way
ANOVA, SigmaStat3.5©, San Jose, CA, U.S.A).
This indicated that the skin will not have a significant depot effect once the patch is removed or
the system is completely shut off and that proper
lockout periods can be programmed based on this
equation.
Y = P + (Y0 − P) × e − k ( X − X e )

(2)

Clonidine also had to be investigated to ensure
that the proper therapeutic levels of drug could be
reached when delivered transdermally, in addition
to if the skin responds to a change in donor concentration allowing a subsequent change in transdermal flux. A similar process of applying a donor
solution followed by a brief washing of the skin
and diffusion cell donor compartment was
repeated, except that this time each donor solution
remained on the skin for 24 hours thereby more
closely representing therapeutic clonidine delivery. The required therapeutic flux values for each
of the different doses were achieved and can also
be seen in Table 1, but it should be noted a short
transition time between doses is not as important
as it is with nicotine, as tapering doses over the
5–10 day treatment are currently used in the
clinical setting.

Future CNT Membrane Application

Amount permeated

It is easy to envision the use of the CNT membrane in therapies not discussed here. Its applicability is wide and the ability to change the rate
of delivery will prove highly beneficial in many

Y0
Span
P

therapeutic areas. Any skin permeable drug is
suitable for CNT membrane delivery as the
membrane is not rate limiting in the way the skin
can be based on size of the molecule or lipophilicity of the drug. CNT membranes do not inhibit
the use of transdermal techniques to increase the
breadth of drugs available for use in transdermal
systems such as prodrugs and codrugs, or the use
of microneedles prior to patch application.23–26
Using these techniques in conjunction with CNT
membranes would not only allow a wider range
of drugs to be delivered, but also provide more
flexibility in programmable rates. By increasing
the permeation through the skin, the range of high
to low flux through the membrane is increased
allowing finer patient to patient tailoring. Additionally, a multiple drug delivery system could
be developed in which two drug reservoirs of
different content and two separate CNT membranes are utilized. This would allow for simultaneous delivery of two drugs at varying rates, or
for transfer between medications without removal
and application of a new transdermal system.
Obviously, size and cost of the device would
increase as the system becomes more advanced,
however the benefits of variable delivery would
outweigh these disadvantages in some therapeutic applications.

Conclusions

Carbon nanotube membranes present a feasible
solution to pitfalls in current smoking cessation
and opioid withdrawal symptom treatments.
Therapeutic transdermal fluxes can be achieved
and the skin responds well to changes in donor
concentrations indicating that the skin will not be
a limiting factor when bias is applied to change
the flux from the patch. This novel method to create a rate changing drug delivery device will not
only increase patient compliance because of the
multiple benefits of using the transdermal route,
but also provide more effective therapy and
improve the quality of life for many addicted
individuals.
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